AMA urges coverage of obesity treatments as payers balk at costs; Study suggests Covid rebound is far more common with Paxlovid than without

Taking stock of the drug industry, from the lab to the medicine chest

November 14, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Brittany Trang/STAT AMA urges coverage of obesity treatments as payers balk at costs Doctors group says patchwork of restrictions is keeping weight loss drugs like Wegovy and Zepbound from patients who need them. By Brittany Trang and Elaine Chen Study suggests Covid rebound is far more common with Paxlovid than without The study's authors and outside experts emphasize that there is no question that Paxlovid is a useful drug that can prevent hospitalization. By Matthew Herper One-quarter of Americans have little to no confidence in scientists to act in public's best interests, per report More Americans lack faith in scientists to act in the public's best interests compared to 2020, a trend with implications for public health. By Anika Nayak

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser